Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Azopt
AZOPT 10 mg/ml eye drops, suspension · Abschnitt 4.5 · PDF-Seite 4–5
HOS-090573 · Präparat HOS-084087
4
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main),
CYP2A6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as ketoconazole,
itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of brinzolamide
by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly. However,
accumulation of brinzolamide is unlikely as renal elimination is the major route. Brinzolamide is not
an inhibitor of cytochrome P-450 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) clotrimazole (HOS-090574) itraconazole (HOS-084516) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T11:23:00Z · SHA-256 d0be850656f9509e71878bc85c7d0b4029d40e9296b4026f616ccfa56bd15b67 · Passage 1cb8578282141ccd7e7c5127a0661aba79ce86b7afac0f06741f560b1122da98 · Zeichen 693–1212 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 10
HOS-116311 · Präparat HOS-094447
Co-administration of darunavir and ritonavir with other medicinal products that inhibit CYP3A may
decrease the clearance of darunavir and ritonavir, which may result in increased plasma concentrations
of darunavir and ritonavir. Co-administration with strong CYP3A4 inhibitors is not recommended and
caution is warranted, these interactions are described in the interaction table below (e.g. indinavir,
azole antifungals such as clotrimazole).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e33336d2c73c404c5fcd8fc19eca7c24e3579d9a5b09ddf954272f5f84cc2f60 · Zeichen 1076–1519 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-116382 · Präparat HOS-094447
Clotrimazole Not Studied. Concomitant systemic use
of clotrimazole and boosted PREZISTA
may increase plasma concentrations of
darunavir and/or clotrimazole.
darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and boosted PREZISTA may or an interruption of colchicine
increase the exposure to colchicine. treatment is recommended in
(CYP3A and/ or P-gp inhibition) patients with normal renal or
hepatic function if treatment with
boosted PREZISTA is required.
For patients with renal or hepatic
impairment colchicine with
boosted PREZISTA is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, artemether Cmin ↔ PREZISTA and
8, 24, 36, 48, and artemether Cmax ↓ 18% artemether/lumefantrine can be
60 hours dihydroartemisinin AUC ↓ 18% used without dose adjustments;
dihydroartemisinin Cmin ↔ however, due to the increase in
dihydroartemisinin Cmax ↓ 18% lumefantrine exposure, the
lumefantrine AUC ↑ 175% combination should be used with
caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) clotrimazole (HOS-090574) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage b3442ef6ceaf51a29429b2633afb31e8bf018bd31dee5803edca0ef04ffe7a51 · Zeichen 42404–44942 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-116506 · Präparat HOS-094447
Medicinal products that affect darunavir/ritonavir exposure
Darunavir and ritonavir are metabolised by CYP3A. Medicinal products that induce CYP3A activity
would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma
concentrations of darunavir and ritonavir (e.g. rifampicin, St John’s Wort, lopinavir).
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may
decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of
darunavir and ritonavir (e.g. indinavir, azole antifungals like clotrimazole). These interactions are
described in the interaction table below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 46154844120d42ab33ccf4262edaed07e7b53e3ff12a2b8932a907e83ff33211 · Zeichen 3015–3702 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-116523 · Präparat HOS-094447
Clotrimazole Not studied. Concomitant systemic use of
clotrimazole and darunavir
co-administered with low dose ritonavir
may increase plasma concentrations of
darunavir and/or clotrimazole.
darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 717df41a52d4c351cc276c736fd3d1822c25d44748732026e5a628379c4af33d · Zeichen 32870–33252 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91
HOS-116584 · Präparat HOS-094447
Co-administration of darunavir and ritonavir with other medicinal products that inhibit CYP3A may
decrease the clearance of darunavir and ritonavir, which may result in increased plasma concentrations
of darunavir and ritonavir. Co-administration with strong CYP3A4 inhibitors is not recommended and
caution is warranted, these interactions are described in the interaction table below (e.g. indinavir,
azole antifungals like clotrimazole).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 226a8503b9308052e824c0ab7c27cc8d92153808170e1812baf09bbd12af0a2a · Zeichen 1021–1461 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100
HOS-116614 · Präparat HOS-094447
Clotrimazole Not studied. Concomitant systemic use of
clotrimazole and boosted PREZISTA
may increase plasma concentrations of
darunavir and/or clotrimazole.
darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and boosted PREZISTA may or an interruption of colchicine
increase the exposure to colchicine. treatment is recommended in
(CYP3A and/ or P-gp inhibition) patients with normal renal or
hepatic function if treatment with
boosted PREZISTA is required.
For patients with renal or hepatic
impairment colchicine with
boosted PREZISTA is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, artemether Cmin ↔ PREZISTA and
8, 24, 36, 48, and artemether Cmax ↓ 18% artemether/lumefantrine can be
60 hours dihydroartemisinin AUC ↓ 18% used without dose adjustments;
dihydroartemisinin Cmin ↔ however, due to the increase in
dihydroartemisinin Cmax ↓ 18% lumefantrine exposure, the
lumefantrine AUC ↑ 175% combination should be used with
caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) clotrimazole (HOS-090574) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8320ed1d6a90756ad97ebcafad72b22fac708f30b38e3c755578b2bedaeadfbe · Zeichen 41875–44413 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-209751 · Präparat HOS-154375
11
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
The effect on tacrolimus
blood concentrations may
remain for several days after
co-administration is
completed.
Moderate or weak CYP3A4 May increase tacrolimus Monitor tacrolimus whole blood
inhibitors: whole blood trough trough concentrations frequently,
antifungal agents (e.g., concentrations and increase starting within the first few days
fluconazole, isavuconazole, the risk of serious adverse of co-administration. Reduce
clotrimazole, miconazole), reactions (e.g., neurotoxicity, tacrolimus dose if needed [see
the macrolide antibiotics QT prolongation) [see section 4.2]. Monitor renal
(e.g., azithromycin), calcium section 4.4]. A rapid increase function, ECG for QT
channel blockers (e.g., in tacrolimus level may prolongation, and other side
nifedipine, nicardipine, occur. effects closely.
diltiazem, verapamil),
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
In vitro the following May increase tacrolimus Monitor tacrolimus whole blood
substances have been shown whole blood trough trough concentrations and reduce
to be potential inhibitors of concentrations and increase tacrolimus dose if needed [see
tacrolimus metabolism: the risk of serious adverse section 4.2].
bromocriptine, cortisone, reactions (e.g., neurotoxicity, Monitor renal function, ECG for
dapsone, ergotamine, QT prolongation) [see QT prolongation, and other side
gestodene, lidocaine, section 4.4]. effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus It is recommended that
rifampicin, phenytoin whole blood trough concomitant use should be
carbamazepine, apalutamide, concentrations and increase avoided. If unavoidable, patients
enzalutamide, mitotane or St. the risk of rejection [see may require an increase in
John’s wort (Hypericum section 4.4]. tacrolimus dose. Changes in
perforatum) Maximal effect on tacrolimus tacrolimus dose should be
blood concentrations may be individualized and adjusted as
achieved 1-2 weeks after co- needed based on tacrolimus
administration. The effect trough concentrations, which
may remain 1-2 weeks after should be assessed at initiation,
completion of the treatment. monitored frequently throughout
(starting within the first few days)
and re-evaluated on and after
completion of the CYP3A4
inducer. After use of the CYP3A4
inducer has ended, tacrolimus
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 1e7cc303a6d0d182851c23281c6a79a17f96d714a9cddc0ab3d6ada78ab947ab · Zeichen 6985–10993 im Abschnitt
Wechselwirkungen · Azarga
AZARGA 10 mg/ml + 5 mg/ml eye drops, suspension · Abschnitt 4.5 · PDF-Seite 6
HOS-120632 · Präparat HOS-095177
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main),
CYP2A6, CYP2B6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as
ketoconazole, itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of
brinzolamide by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly.
However, accumulation of brinzolamide is unlikely as renal elimination is the major route.
Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) clotrimazole (HOS-090574) itraconazole (HOS-084516) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T11:25:00Z · SHA-256 31d2d9680fb40d91c0814e4a11af0fd7afd46b076a9707025daaf594939f4a9e · Passage 2cbabca0a503edbfca13e55800dcff6df8fb142888aabfac4184f448b0529203 · Zeichen 682–1206 im Abschnitt
Wechselwirkungen · Lojuxta
Lojuxta 2 mg hard capsules Lojuxta 5 mg hard capsules Lojuxta 10 mg hard capsules Lojuxta 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-127355 · Präparat HOS-096397
Weak CYP3A4 inhibitors are When administered with atorvastatin, the
expected to increase the exposure of dose of lomitapide should either be taken
lomitapide when taken 12 hours apart or be decreased by half (see
simultaneously. section 4.2). The dose of lomitapide should
be taken 12 hours apart from any other
When lomitapide 20 mg was concomitant weak CYP3A4 inhibitors.
co-administered simultaneously with Examples of weak CYP3A4 inhibitors
atorvastatin, a weak CYP3A4 include: alprazolam, amiodarone,
inhibitor, lomitapide AUC and Cmax amlodipine, atorvastatin, azithromycin,
increased approximately 2-fold. bicalutamide, cilostazol, cimetidine,
When the dose of lomitapide was ciclosporin, clotrimazole, fluoxetine,
taken 12 hours apart from fluvoxamine, fosaprepitant, ginkgo,
atorvastatin, no clinically meaningful goldenseal, isoniazid, ivacaftor, lacidipine,
increase in lomitapide exposure was lapatinib, linagliptin, nilotinib,
observed. oestrogen-containing oral contraceptives,
pazopanib, peppermint oil, propiverine,
When lomitapide 20 mg was co- ranitidine, ranolazine, roxithromycin, Seville
administered simultaneously or oranges, tacrolimus, ticagrelor and tolvaptan.
12 hours apart with ethinyl This list is not intended to be comprehensive
estradiol/norgestimate, a weak and prescribers should check the prescribing
CYP3A4 inhibitor, no clinically information of medicinal products to be co-
meaningful increase in lomitapide administered with Lojuxta for potential
exposure was observed. CYP3A4 mediated interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) lacidipine (HOS-113865) norgestimate (HOS-110544) cilostazol (HOS-111550) cimetidine (HOS-085835) atorvastatin (HOS-086304) alprazolam (HOS-086171) roxithromycin (HOS-127365) propiverine (HOS-127363) peppermint oil (HOS-127362) estradiol (HOS-090751) amlodipine (HOS-086287) azithromycin (HOS-088112) clotrimazole (HOS-090574) bicalutamide (HOS-127356) tolvaptan (HOS-109429) fosaprepitant (HOS-117427) lapatinib (HOS-122565) ivacaftor (HOS-109475) tacrolimus (HOS-085202) linagliptin (HOS-124309) pazopanib (HOS-122551) fluoxetine (HOS-085946) ranitidine (HOS-085660) amiodarone (HOS-085596) fluvoxamine (HOS-085908) ranolazine (HOS-086141) isoniazid (HOS-088590) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T14:24:00Z · SHA-256 56c36935b5cda4380e359902f1acbc5ec5bb081beeb96ca75e5ad86521fcd98c · Passage 714d59bc1bbe3ac0c5d4eeaa178f455a97b56caa11d4ced4ec39de50572ee7d0 · Zeichen 2870–5037 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-134470 · Präparat HOS-097580
Medicinal products that affect darunavir/ritonavir exposure
Darunavir and ritonavir are metabolised by CYP3A. Medicinal products that induce CYP3A activity
would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma
concentrations of darunavir and ritonavir (e.g. rifampicin, St John’s wort, lopinavir).
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may
decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of
darunavir and ritonavir (e.g. indinavir, azole antifungals like clotrimazole). These interactions are
described in the interaction table below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 7f5ec8ac95904b9c22f02d7cea5470b7762211105923f53986a35acd0ae78545 · Zeichen 3017–3704 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-134496 · Präparat HOS-097580
Clotrimazole Not studied. Concomitant systemic use
of clotrimazole and darunavir co-
administered with low dose ritonavir
may increase plasma concentrations of
darunavir and/or clotrimazole.
Darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage ddc51b762ccf9776b81de2cb9b172bc59dff8f2fdab61097f91d33ce74fb9320 · Zeichen 33590–34030 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-134585 · Präparat HOS-097580
Co-administration of darunavir and ritonavir with other medicinal products that inhibit CYP3A may
decrease the clearance of darunavir and ritonavir, which may result in increased plasma concentrations
of darunavir and ritonavir. Co-administration with strong CYP3A4 inhibitors is not recommended and
caution is warranted, these interactions are described in the interaction table below (e.g. indinavir,
azole antifungals like clotrimazole).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) clotrimazole (HOS-090574) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 226a8503b9308052e824c0ab7c27cc8d92153808170e1812baf09bbd12af0a2a · Zeichen 1022–1462 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-134623 · Präparat HOS-097580
Clotrimazole Not studied. Concomitant systemic
use of clotrimazole and boosted
darunavir may increase plasma
concentrations of darunavir and/or
clotrimazole.
Darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage or
colchicine and boosted darunavir an interruption of colchicine
may increase the exposure to treatment is recommended in patients
colchicine. with normal renal or hepatic function
(CYP3A and/ or P-gp inhibition) if treatment with boosted darunavir is
required. For patients with renal or
hepatic impairment colchicine with
boosted darunavir is contraindicated
(see sections 4.3 and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, 8, artemether Cmin ↔ darunavir and
24, 36, 48, and 60 hours artemether Cmax ↓ 18% artemether/lumefantrine can be used
dihydroartemisinin AUC ↓ 18% without dose adjustments; however,
dihydroartemisinin Cmin ↔ due to the increase in lumefantrine
dihydroartemisinin Cmax ↓ 18% exposure, the combination should be
lumefantrine AUC ↑ 175% used with caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and The combination of rifapentine and
Rifapentine rifampicin are strong CYP3A boosted darunavir is not
inducers and have been shown to recommended.
cause profound decreases in
concentrations of other protease The combination of rifampicin and
inhibitors, which can result in boosted darunavir is contraindicated
virological failure and resistance (see section 4.3).
development (CYP450 enzyme
induction). During attempts to
overcome the decreased exposure
by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) clotrimazole (HOS-090574) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 64fdfa97cef778c7193c87ea0168964e1f464c278d0316c8ae901fe34d28a3c8 · Zeichen 40700–43992 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-138467 · Präparat HOS-098200
Co-administration of Symtuza and other medicinal products that inhibit CYP3A may decrease the
clearance of darunavir and cobicistat and may result in increased plasma concentrations of darunavir
and cobicistat (e.g. azole antifungals like clotrimazole). These interactions are described in the
interaction table below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clotrimazole (HOS-090574)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage f230d0f81162f5861f3cdda8faaa159289664b0f2bae4f43f3bbee254d068b74 · Zeichen 2033–2351 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-138484 · Präparat HOS-098200
Based on theoretical considerations
Amitriptyline DRV/COBI is expected to increase
Desipramine these anti-depressant plasma
Imipramine concentrations.
Nortriptyline (CYP2D6 and/or CYP3A
Trazodone inhibition)
ANTI-DIABETICS
Metformin Based on theoretical considerations Careful clinical monitoring and
DRV/COBI is expected to increase dose adjustment of metformin is
metformin plasma concentrations. recommended in patients who are
(MATE1 inhibition) taking Symtuza.
ANTIEMETICS
Domperidone Not studied. Co-administration of
domperidone with Symtuza is
contraindicated.
ANTIFUNGALS
Clotrimazole Based on theoretical considerations Caution is warranted and clinical
Fluconazole DRV/COBI is expected to increase monitoring is recommended.
Itraconazole these antifungal plasma When co-administration is
concentrations, and darunavir, required, the daily dose of
Isavuconazole cobicistat and/or tenofovir itraconazole should not exceed
Posaconazole alafenamide plasma concentrations 200 mg.
may be increased by the
antifungals.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) clotrimazole (HOS-090574) domperidone (HOS-114656) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) posaconazole (HOS-085622) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 061584a4f2d3686461b02951b37d12cd2e74b66b2c1221794b17ed1d0cb7ecd1 · Zeichen 15577–17097 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139158 · Präparat HOS-098290
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics (e.g., neurotoxicity, QT prolongation) is unavoidable, consider
telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, (see section 4.4). the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors (e.g., tacrolimus levels may occur, as tacrolimus the next day at a
ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase >5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with and tacrolimus exposure may increase needed based on tacrolimus
without dasabuvir), >50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, ceritinib. The effect on tacrolimus blood first few days) and re-
Strong interactions have also concentrations may remain for evaluated on and after
been observed with the several days after co-administration completion of the CYP3A4
macrolide antibiotic is completed. inhibitor. Upon completion,
erythromycin. appropriate dose and dosing
frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) (see section 4.4). A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed (see
azithromycin), calcium may occur. section 4.2). Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68eefd97f11d29951c1cb7e82fce1c09e7dec9a4f694ee7101cde8ef1e7bf3ae · Zeichen 3968–8645 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.